Human monocytes cultured on adherent IgG produce a specific IL-1 inhibitor that functions as a receptor antagonist (IL-ira). This molecule has been purified, sequenced, cloned as a cDNA, and expressed in Escherichia coli. Recombinant IL-ira has 17,000 mol wt and binds to IL-i receptors on T lymphocytes, synovial cells, and chondrocytes with an affinity nearly equal to that of IL-1. These studies have examined some biological properties of purified recombinant human IL-ira. This protein exhibits a dose-responsive inhibition of IL-la and IL-1,@ augmentation of PHA-induced murine thymocyte proliferation.
Introduction IL-I has numerous effects on both immune and inflammatory cells, including augmentation of T and B lymphocyte function (1) . In addition, IL-I may be a mediator of tissue destruction in chronic autoimmune or inflammatory diseases. These diseases include juvenile-onset diabetes mellitus, where IL-I may directly or indirectly induce toxicity to A cells in the islets of Langerhans (2) . In rheumatoid arthritis IL-I may contribute to joint damage through stimulating PGE2 and collagenase production in synovial fibroblasts and chondrocytes (3) .
Because of the pleiotropic effects of IL-1 on many different target cells, and purported roles in normal physiology and in pathophysiology, it has been hypothesized that natural inhibitors of IL-I might exist (4) . IL-1 inhibitory activities have been described in human body fluids and in the supernatants of cultured human or animal cells or cell lines (reviewed in Arend et al. [5] ). In most cases, these biological activities have not been further characterized and their mechanisms of action have not been determined. However, IL-I inhibitors could be acting at multiple levels; these include decreasing synthesis and release of IL-1, adhering to IL-in solution, blocking IL-I receptor binding, or interfering with IL-i-induced signal transduction at a post-receptor level. For example, the ubiquitous urinary protein uromodulin binds to IL-I in solution (6) and deoxyribonuclease I from human urine interferes with detection of IL-I in the thymocyte assay, possibly by releasing free thymidine (7) .
An IL-I inhibitory activity has been described in the supernatants of human monocytes cultured on adherent IgG or immune complexes (5, 8) and in the urine of patients with fever or myelomonocytic leukemia (9-1 1). This specific IL-I inhibitor of 22,000 mol wt blocks the binding of IL-i a or IL-1I# to IL-i receptors on the murine thymoma cell line EL4-6. 1 (5, 1 1). In recent studies this monocyte-derived molecule has been purified and partially sequenced (12) . This native molecule represents a unique new protein that exists in two forms, a 22,000-mol wt glycosylated form with some microheterogeneity, and an nonglycosylated 17,000-mol wt form. A complementary DNA has been cloned and expressed in Escherichia coli with production of recombinant 17,000-mol wt molecules (13). Similar to the crude or semipurified IL-I inhibitor, the recombinant molecule blocks IL-I binding to the IL-I receptor on EL4-6. 1 cells (5, 1 1, 12) . Furthermore, this molecule has no detectable IL-I agonist effects on human foreskin fibroblasts and therefore functions as an IL-1 receptor antagonist (IL-Ira)' (5, 10, 12) . The results of studies on biological properties of purified recombinant 17,000-mol wt IL-Ira are reported in this paper.
Methods
Recombinant IL-Ira. Expression of IL-Ira in Escherichia coli was carried out as recently described (13). The recombinant IL-Ira of 17,000 mol wt was purified from the bacterial lysates by successive cation and anion-exchange column chromatography. The IL-Ira was > 95% pure as determined by silver staining after SDS-PAGE. The IL-Ira protein concentration was determined by OD280 using a calculated extinction coefficient of 0.776 (mg/ml)-'. The recombinant IL-lra was stored at -70'C in small aliquots in PBS with 10% glycerol.
1. Abbreviation used in this paper: IL-1 ra, interleukin I receptor antagonist.
A fresh aliquot was thawed for each experiment, Stored in this fashion for up to 6 mo, the recombinant IL-Ira demonstrated a full maintenance of biological activities.
Effects of IL-Ira on thymocyte proliferation. The recombinant IL-I ra was assayed against IL-I a or -iB augmentation of PHA-induced proliferation ofthymocytes from C3H/HeJ mice, as recently described (5) . Recombinant human IL-la (compliments of Dr. Peter T. Lomedico, Hoffmann-La Roche, Inc., Nutley, NJ) and recombinant human IL-I13 (compliments of Dr. John Childs, Synergen, Inc., Boulder, CO) were used at baseline concentrations of 56 pg/ml IL-I a and 207 pg/ml IL-113, respectively. These concentrations were functionally equivalent to 3 U/ml ofboth types of IL-I, reflecting the fact that the recombinant IL-I a possessed a higher specific activity than did the IL-I fl. A unit of IL-I activity was defined as that amount giving 50% maximal augmentation in the murine thymocyte assay. A concentration of 3 U/ml of IL-la or IL-1,8 yielded 80% of maximal stimulation of thymocytes. Serial dilutions of the recombinant IL-lra were mixed with the single amount of IL-la or IL-1 3 before adding to the thymocytes in 96-well plates. The cells were cultured in RPMI-1640 medium (Gibco Laboratories, Grand Island, NY) with 10% low-endotoxin FCS (HyClone Laboratories, Logan, UT) for 4 d at 370C and 5% CO2. Thymocyte proliferation was measured by the colorimetric method with 3-(4,5-dimethylthiazol-2-y 1 )-2,5-diphenyl tetrazolium bromide (MTT), as described (5, 14). Recombinant. IL-lra also was tested against IL-2 (Amgen Biologicals, Thousand Oaks, CA) effects in the murine thymocyte assay.
Effects ofIL-i ra on IL-I stimulation ofsynovial cells and chondrocytes. The recombinant IL-Ira also was assayed for inhibitory activity against IL-I induction of biological responses in synovial cells and chondrocytes. Human synovial cells (15) and rabbit articular chondrocytes (16) were obtained and cultured adherent to plastic as recently described (5) . Chondrocytes were used either in the original culture or first passage to avoid problems with dedifferentiation. Rheumatoid synovial cells were used at confluency in the first through third passage. Again, 3 U/ml of human IL-la or IL-1I3 were mixed with increasing amounts of IL-lra and added to the cells in DME with 5% NuSerum (Collaborative Research, Inc., Waltham, MA). These amounts of IL-la and IL-,I yielded submaximal stimulation of the synovial cells and chondrocytes. After 16 h of culture at 370C and 5% CO2 supernatants were harvested for determination of PGE2 concentration by a specific ELISA (17) . Initial experiments performed in the absence of any added serum indicated that PGE2 levels in cell supernatants were low and highly variable. ELISAs also were used to measure protein concentrations oflatent and active collagenase (18) and tissue inhibitor of metalloproteinases (19) in supernatants of cultured rheumatoid synovial cells.
Results
Inhibition ofIL-la and IL-i]1 augmentation ofmurine thymocyte proliferation. The recombinant IL-Ira first was assayed against 3 U/ml IL-I a or IL-1I3 in the murine thymocyte assay. Parallel dose-responsive inhibition curves were obtained with IL-I ra and either form of IL-I (Fig. 1) . 50% inhibition of IL-Ia and IL-1I3 effects was observed with 2 and 1 ng/ml IL-Ira, respectively. These amounts of IL-Ira are 40 times the concentration of IL-Ia and 5 times the concentration of IL-113 used to stimulate the thymocytes. The effects of a submaximal amount of IL-2 (10 U/ml) in the thymocyte assay were not inhibited by IL-Ira in concentrations up to 100 ng/ml (data not shown). In addition, these amounts of IL-Ira alone exhibited no stimulatory or agonist effects on the murine thymo- bit articular chondrocytes. These cells were stimulated with 3 U/ml of IL-Ia or IL-113. Examination of PGE2 production revealed similar dose-responsive inhibition curves with serial concentrations of IL-I ra cultured with IL-I and either synovial cells (Fig. 2) or chondrocytes (Fig. 3) . In addition, the IL-Ira inhibited IL-I stimulation of collagenase production by the human synovial cells in a similar fashion (Fig. 4) . IL-Ira alone in concentrations up to 100 ng/ml exhibited no agonist effects on either synovial cells or chondrocytes. Unstimulated synovial cells produced large amounts of tissue inhibitor of metalloproteinases with no alterations observed with IL-i a or IL-1 or with IL-Ira (data not shown).
Comparison of the relative potencies of IL-Ira against IL-I a or IL-113 stimulation of the two cell types revealed some interesting differences. 50% inhibition of IL-Ia or IL-1 3 induction of PGE2 production by the synovial cells was observed with 1.6 and 2.8 ng/ml IL-Ira, respectively (Table 1) . These protein concentrations were 30-and 10-fold greater than the concentrations of IL-Ia or IL-113 used to stimulate the cells. The rabbit chondrocytes required higher amounts of IL-Ira, 5.7 and 15.5 ng/ml, respectively, to yield 50% inhibition of IL-i a and IL-113 stimulation (Table I) . These concentrations are up to 100-fold higher than the stimulating levels of IL-1.
Discussion
The experiments reported herein examine the biological activities of purified recombinant monocyte-derived IL-Ira, a receptor antagonist of IL- monocyte supernatants (5). The recombinant IL-lra exhibited a dose-responsive inhibition of IL-1 effects on murine thymocytes, human synovial cells, and rabbit articular chondrocytes. The inhibition of IL-2 augmentation of murine thymocyte proliferation observed in the previous studies probably was due to another protein than IL-1ra in the crude monocyte supernatant. This conclusion is supported by the observation that highly purified native IL-lra, like the recombinant mole- cule, does not inhibit IL-2 effects on thymocytes (Arend, W. P., and C. H. Hannum, unpublished observations). The majority of the native monocyte-derived IL-lra is a 22,000-mol wt form that is glycosylated (12) . Small amounts of the nonglycosylated form of the same unique molecule (17,000 mol wt) also are present in IgG-induced monocyte supernatants (12, 13 affinity as IL-I a or IL-1# ( 1 2).2 An explanation for the apparent differences in IL-Ira potency between direct binding to the IL-I receptor and in biological activities probably lies in the fact that all these cell types are exquisitely responsive to tiny amounts of IL-1. Maximal biological responses can be observed when < 5% of available receptors are occupied by IL-1. Thus, although IL-Ira and IL-I bind to receptors in an equimolar fashion, much higher concentrations of IL-Ira are necessary to block IL-I occupancy of only a few receptors.
IL-Ira alone exhibited no agonist effects on murine thymocytes, human synovial cells and rabbit articular chondrocytes. Furthermore, IL-Ira blocked IL-1-induced PGE2 production by human foreskin fibroblasts (13) and adhesion molecule mRNA increases in human umbilical vein endothelial cells (20) without exhibiting any agonist effects on these cells. Although this molecule has been characterized as an IL-I receptor antagonist, further studies are necessary to investigate whether IL-Ira has agonist effects on any target cells responsive to IL-1.
The biological relevance of IL-Ira to normal physiology of IL-1, or to the possible role of IL-I in pathophysiology, remains to be established. IL-Ira binds to IL-I receptors on T lymphocytes (5, 11, 12) , synovial cells and chondrocytes,2 but not to the second class of IL-I receptors that is present on a murine pre-B lymphocyte cell line (12, 21, 22) . As monocytes mature into macrophages, the cells produce less IL-I and more IL-Ira (23, 24) . IL-Ira production by human macrophages is further stimulated by culture in granulocyte/macrophage colony-stimulating factor (GM-CSF) (23, 24) . IL-Ira may represent a natural receptor antagonist that limits the effects of IL-I primarily in the microenvironment of tissue macrophages. IL-I ra may be of therapeutic value in human diseases possibly mediated by pathophysiological effects of IL-1.
